Alphatec Hlds (ATEC) Stock Forecast & Price Target

Alphatec Holdings is viewed favorably because it is showing robust 20% procedure growth, a 25% increase in new users, and continued record surgeon adoption, which together suggest durable demand and expanding clinical acceptance. Its operating performance also supports the bullish case, with adjusted gross margin at 71.9%, adjusted operating margin at 9.8%, adjusted EBITDA margin at 17.3%, and free cash flow of $6M versus roughly breakeven guidance, indicating improving execution and leverage. Looking ahead, the outlook is further strengthened by expected sustainable above-peer growth, EOS-driven implant pull-through, and the potential for better-than-expected profitability in 2027 and beyond as the Enabling Technology story develops.

Alphatec Holdings is facing a negative setup because 3Q disappointed as biologics attachment weakened again, driving revenue to $221M versus $225M consensus and pulling revenue per case down 5% despite 20% procedure growth. Management then cut 2026 guidance to about $862M of revenue, $137M of adjusted EBITDA, and $10M of FCF, signaling that a $20M revenue reduction was only partially offset by resilient margins, while a slower U.S. spine market and pricing pressure threaten the durability of growth. The risk is that biologics may stall for a year or more, making the 2027 target harder to reach and leaving the stock exposed to lower top-line growth, market-share pressure, and stalling profitability.